关键数据公布!口服司美格鲁肽减重III期研究结果出炉

医药地理
Sep 28

诺和诺德近日公布口服司美格鲁肽(25mg)III期研究数据,治疗64周后患者平均体重下降16.6%,超三分之一用药者减重超20%,疗效与注射剂型相当。礼来口服替尔泊肽也于早前披露类似积极结果,36mg剂量组患者平均减重7.3kg。数据显示,口服剂型在有效性和患者接受度方面展现出显著优势,为减重治疗提供了更便捷的新选择。目前GLP-1类减重药物市场呈现高速增长态势。2025年上半年,诺和诺德司美格...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10